Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Pharmacia Flexes Market Strength: More Bulk For Medicaid/Medicare

Executive Summary

Pfizer's $60 bil. stock acquisition of Pharmacia would create a combined company with over $23 bil. in annual U.S. drug sales with commensurate influence and bargaining power with large Rx drug purchasers

You may also be interested in...



Sanofi-Aventis Deal Means More Leverage With Managed Care

Sanofi's $65 bil. merger with Aventis will offer the combined entity additional negotiating clout with large U.S. drug purchasers, Exec VP-Operations Hanspeter Spek said during an April 26 conference call

Sanofi-Aventis Deal Means More Leverage With Managed Care

Sanofi's $65 bil. merger with Aventis will offer the combined entity additional negotiating clout with large U.S. drug purchasers, Exec VP-Operations Hanspeter Spek said during an April 26 conference call

AdvancePCS Gives 80% Of Rebates To Clients, Sees Discounts Increasing

AdvancePCS retains less than 20% of manufacturer rebates, the pharmacy benefit management company told a July 25 conference call

Related Content

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel